- Home
- GOCO vs BTAI Comparison
GOCO vs BTAI Comparison
Compare GOCO & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GOCO | BTAI |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.3M | 43.7M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GOCO | BTAI |
|---|---|---|
| Price | $1.76 | $1.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $5.00 | ★ $26.67 |
| AVG Volume (30 Days) | 37.9K | ★ 494.6K |
| Earning Date | 02-26-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $738,338,000.00 | $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $265.60 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.56 | N/A |
| 52 Week Low | $1.83 | $1.17 |
| 52 Week High | $21.00 | $8.08 |
Technical Indicators
Market Signals| Indicator | GOCO | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 32.47 | 44.02 |
| Support Level | $1.83 | $1.36 |
| Resistance Level | $2.10 | $1.72 |
| Average True Range (ATR) | 0.16 | 0.12 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 1.35 | 45.10 |
Price Performance
Historical ComparisonAbout GOCO GoHealth Inc.
GoHealth Inc is a health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers' peace of mind when making healthcare decisions so consumers can focus on living life. It offers Medicare plans, including, but not limited to, Medicare Advantage, Medicare Supplement and prescription drug plans. Its proprietary technology platform leverages modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer's specific needs.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.